Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes.

Shan LangJin YangKun YangLiangbiao GuXiaona CuiTianjiao WeiJunling LiuYunyi LeHaining WangRui WeiTianpei Hong

Published in: BMJ open diabetes research & care (2020)

The elevated circulating GLP-1 level by GCGR mAb is mainly due to intestinal L-cell proliferation and GLP-1 production, which may be mediated via GLP-1R/PKA signaling pathways. Therefore, GCGR mAb represents a promising strategy to improve glycemic control and restore the impaired GLP-1 production in T2D.

Keyphrases

type diabetes
glycemic control
cell proliferation
cell cycle
blood glucose
pi k akt
cardiovascular disease
oxidative stress
epithelial mesenchymal transition